Trial description:
An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation
Contact name:
Dr Pippa Corrie
Trial start date:
Thursday, May 10, 2018
Trial end date:
Saturday, April 30, 2022
Trial tumour type:
Pancreatic
Show on Radiotherapy:
No
